The present study provides evidence that suppression of Nrf2 transcription by wild-type p53, occurring via decreased Sp1 binding to the Nrf2 promoter, may confer cisplatin sensitivity, a favorable chemo-response, thereby leading to favorable outcomes in lung cancer patients. Here, NFE2L2 is linked to lung carcinoma.